Lantern Pharma
LTRN
33 hedge funds and large institutions have $6.91M invested in Lantern Pharma in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 3 closing their positions.
720% more call options, than puts
Call options by funds: $82K | Put options by funds: $10K
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
10% more funds holding
Funds holding: 30 → 33 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.67% less ownership
Funds ownership: 21.06% → 20.39% (-0.67%)
30% less capital invested
Capital invested by funds: $9.89M → $6.91M (-$2.98M)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$122K |
| 2 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$59.5K |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$57.4K |
| 4 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$45.5K |
| 5 |
Renaissance Technologies
New York
|
+$38.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$83.9K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$79K |
| 3 |
Two Sigma Investments
New York
|
-$69.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$38.2K |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$34.3K |
LTRN Hedge Fund Activity: Q4 2025 in Review
33 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q4 2025, worth a combined $6.91M — down 30% from $9.89M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LTRN positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $122K. The largest seller was UBS Group, cutting an estimated $83.9K.
- 33 institutional investors held Lantern Pharma (LTRN) as of Q4 2025, up from 30 in Q3 2025.
- Funds reported $6.91M of Lantern Pharma stock for Q4 2025, down 30% quarter-over-quarter.
- 6 funds opened new Lantern Pharma positions in Q4 2025 and 3 closed out, a net change of +3 holders.
- The largest Lantern Pharma buyer in Q4 2025 was Citadel Advisors, an estimated $122K added.
- The largest Lantern Pharma seller in Q4 2025 was UBS Group, an estimated $83.9K sold.
Based on aggregated 13F filings for Q4 2025.